Showing results (11-20 of 639) with videos related to

Sort By:
Pageof 64
Journal of Gastroenterology|June 13, 2025
Distinct age-related effects of homologous recombination deficiency on genomic profiling and treatment efficacy in gastric cancerYoshie Maki, Yoshiyasu Kono, Toshiki Ozato, et al.
Scientific Reports|January 6, 2016
An Intriguing Correlation Based on the Superimposition of Residue Pairs with Inhibitors that Target Protein-Protein InterfacesMasakazu Nakadai, Shuta Tomida, Kazuhisa Sekimizu
JCO Precision Oncology|September 19, 2024
Response to Imatinib in a Patient With Gastric Adenocarcinoma With <i>KIT</i> Q556_K558 In-Frame Deletion: A Case ReportKiichiro Ninomiya, Daisuke Ennishi, Kunio Okamoto, et al.
Carcinogenesis|March 17, 2018
Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFRHidejiro Torigoe, Hiromasa Yamamoto, Masakiyo Sakaguchi, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|January 23, 2026
Longitudinal Spatial Transcriptomics Reveals the Molecular Dynamics of Pulmonary Artery Remodeling in Pulmonary Arterial HypertensionHaruki Choshi, Seiichiro Sugimoto, Shuta Tomida, et al.
Japanese Journal of Clinical Oncology|October 21, 2025
Remarkable response of gastric adenocarcinoma with FGFR2-TRIM44 fusion to pemigatinib: a case reportMiho Fujiwara, Kiichiro Ninomiya, Emi Chikuie, et al.
Molecular Cancer Research : MCR|November 23, 2018
Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer CellsKei Namba, Kazuhiko Shien, Yuta Takahashi, et al.
Cancer Science|February 22, 2018
Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancerTakahiro Yoshioka, Kazuhiko Shien, Kei Namba, et al.
Oncology Letters|March 12, 2019
Anti-tumor effect of neratinib against lung cancer cells harboring <i>HER2</i> oncogene alterationsYusuke Ogoshi, Kazuhiko Shien, Takahiro Yoshioka, et al.
Oncology Letters|September 30, 2017
Elacridar, a third-generation ABCB1 inhibitor, overcomes resistance to docetaxel in non-small cell lung cancerHaiyang Chen, Kazuhiko Shien, Ken Suzawa, et al.
Pageof 64